Monitor FDA review progress toward the February 28, 2027 PDUFA date. A positive decision would be transformative, while a negative outcome would significantly impair the company's prospects. Post-IPO, expect volatility as the market prices in binary risk.
Executive Summary
Apnimed is offering 10,000,000 shares of common stock in its IPO at an expected price range of $14.00-$16.00 per share. The company is a late-stage clinical biopharmaceutical firm developing Oxnimbi (AD109), an oral therapy for obstructive sleep apnea. The NDA was accepted by the FDA in July 2026 with a PDUFA date of February 28, 2027. Net proceeds of approximately $134.6 million (midpoint) will primarily fund regulatory approval and commercialization efforts. The company has a history of operating losses and a going concern uncertainty, but IPO proceeds are expected to fund operations through June 2028.
Key Financial Metrics
Key Facts
- NDA for Oxnimbi accepted by FDA with PDUFA date of February 28, 2027
- Phase 3 trials (LunAIRo and SynAIRgy) met primary and key secondary endpoints
- Preliminary cash and cash equivalents of $172.8 million as of June 30, 2026
- Offering 10,000,000 shares at $14.00-$16.00 per share; net proceeds ~$134.6 million
- Net loss from continuing operations of $58.1 million in 2025; accumulated deficit of $329.6 million as of March 31, 2026
Financial Impact
IPO expected to raise ~$134.6M net; funds allocated ~$228.8M for regulatory approval and commercial launch of Oxnimbi, remainder for R&D and working capital
Risk Factors
- Regulatory approval uncertainty – FDA may require additional data or reject the NDA
- Dependence on a single product candidate (Oxnimbi) for future revenue
- Substantial doubt about going concern prior to IPO; ongoing need for capital
- Competition from PAP devices, GLP-1 agonists, and other emerging therapies
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1/A Filing (Primary) | 0001193125-26-316811 |
| Document: apni-ex3_5.htm | 0001193125-26-316811 |
| Document: apni-ex10_29.htm | 0001193125-26-316811 |
| Document: apni-ex10_36.htm | 0001193125-26-316811 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 5, 2026 11w ago | Insider Cluster | $27.88 $27.81 | ▼ −0.25% | ▼ −0.85% | $18.95 (−32.03%) |
Aug 3, 2026 12w ago | Insider Buy | $25.71 $26.85 | ▲ +4.43% | ▲ +5.67% | $18.95 (−26.29%) |
Jul 31, 2026 12w ago | 424B4 | $25.00 $26.25 | ▲ +5.00% | ▲ +3.76% | $18.95 (−24.20%) |
Jul 31, 2026 12w ago | EFFECT | $25.00 $29.71 | ▲ +18.84% | ▲ +15.85% | $18.95 (−24.20%) |
Jul 30, 2026 12w ago | 3 | $25.00 $29.71 | ▲ +18.84% | ▲ +15.85% | $18.95 (−24.20%) |
Jul 27, 2026 13w ago | S-1/A | — | awaiting T+20 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers